Visterra, Inc. has recently received a contract worth up to $204.5 million to further develop its new monoclonal antibody to treat influenza A.
Visterra, Inc. is a
clinical-stage biotechnology company that identifies unique disease
targets and creates therapeutics for infectious diseases with its
proprietary technology platform.
The contract was provided by the Biomedical Advanced Research and Development Authority
(BARDA). The funds will last for five years and will apply specifically
to the new treatment, called VIS410.
“We are pleased that BARDA has awarded this contract covering the
development of VIS410,” Brian Pereira, MD, President and Chief Executive
Officer of Visterra, said.
The contract finances clinical trials, pre-clinical toxicology
studies, optimized manufacturing processes, and materials for clinical
trials, as well as any other related regulatory activities that will
further develop VIS410.
“Visterra is proud to play an important role
in addressing the significant public health concern of seasonal
influenza A and the growing threat of emerging strains of influenza A,” Pereira said.
“This award from BARDA will support the continued development of VIS410,
our lead product candidate, which was designed and engineered using our
proprietary technology platform.”
Influenza A is seasonal but has the potential to become pandemic which has led to attempts to develop effective treatments for the illness.
